赫斯佩里丁通过调节肠道微生物群来改善由β-上腺激活诱导的心脏纤维化
Xia Liu1, Weiwei Ju1, Erjiao Qiang2
1The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
概括
赫斯佩里丁是一种天然化合物,通过恢复肠道微生物群平衡,有效地减少小鼠心脏纤维化. 这项研究突出了针对肠心轴的心血管疾病的新型治疗方法.
科学领域:
- 心血管研究研究心血管研究
- 微生物组科学 微生物组科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏纤维化是心血管疾病的关键因素,构成全球健康风险.
- 肠道微生物群的改变越来越多地与心血管病理有关.
- 赫斯佩里丁显示出潜在的心脏保护作用和肠道健康益处.
研究的目的:
- 为了研究hesperidin在改善心脏纤维化的机制.
- 探索肠道微生物群调节在hesperidin对心脏纤维化影响中的作用.
- 建立hesperidin,肠道微生物群和心脏纤维化治疗之间的联系.
主要方法:
- 在C57BL/6小鼠中使用异二醇诱导心脏纤维化.
- 通过心声学评估心脏功能.
- 纤维化标志物使用马森染色,西部斑点和qPCR进行评估.
- 用16S rRNA基因测序分析肠道微生物组成.
主要成果:
- 在小鼠中,hesperidin显著减轻了异二醇诱导的心脏纤维化.
- 赫斯皮里丁治疗改善了纤维化小鼠的肠道微生物群失生症.
- 在肠道微生物群枯竭的小鼠中证实了效应,强调了微生物群的作用.
结论:
- 赫斯佩里丁通过调节肠道微生物群和相关代谢物来改善心脏纤维化.
- 这项研究提供了第一个证据,将hesperidin的心脏保护作用与肠道微生物群调节联系起来.
- 针对肠道微生物群的传统医学,如hesperidin,为心脏纤维化治疗提供了一个有希望的策略.
相关概念视频
01:17Antihypertensive Drugs: Action of β1 Blockers
2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:22Heart Failure Drugs: β-Blockers
2.9K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.9K
01:29Heart Failure II: Pathophysiology
2.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.1K
01:30Heart Failure V: Medical Management
641
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641
01:29Cardiomyopathy V: Interprofessional Care
761
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
761